A detailed history of Xtx Topco LTD transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Xtx Topco LTD holds 14,801 shares of PTGX stock, worth $577,535. This represents 0.05% of its overall portfolio holdings.

Number of Shares
14,801
Holding current value
$577,535
% of portfolio
0.05%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$33.72 - $47.33 $499,089 - $700,531
14,801 New
14,801 $665,000
Q3 2023

Nov 13, 2023

BUY
$16.68 - $23.66 $269,198 - $381,848
16,139 New
16,139 $269,000
Q4 2022

Feb 14, 2023

SELL
$7.36 - $11.17 $190,491 - $289,101
-25,882 Reduced 66.66%
12,942 $141,000
Q3 2022

Nov 14, 2022

BUY
$7.86 - $11.71 $205,939 - $306,813
26,201 Added 207.57%
38,824 $327,000
Q2 2022

Aug 15, 2022

BUY
$7.06 - $25.52 $89,118 - $322,138
12,623 New
12,623 $100,000

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $1.92B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Xtx Topco LTD Portfolio

Follow Xtx Topco LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Xtx Topco LTD, based on Form 13F filings with the SEC.

News

Stay updated on Xtx Topco LTD with notifications on news.